Sacituzumab Govitecan Yields Consistent Benefit in Platinum-Ineligible mUCFebruary 18th 2023
Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.
Select Biomarkers May be Predictive of Enfortumab Vedotin Efficacy in Urothelial CancerFebruary 18th 2023
Findings from the phase 2 UNITE study indicate that certain biomarkers may help inform clinical decision making and sequencing in patients with advanced urothelial carcinoma.
Niraparib Combination Continues to Improve Outcomes in Metastatic CRPCFebruary 17th 2023
Niraparib plus abiraterone and prednisone continue to improve outcomes among patients with metastatic, castration-resistant prostate cancer and HRR gene alterations, according to interim data from the MAGNITUDE study.
Darolutamide Demonstrates Long-Term Safety in Nonmetastatic CRPCFebruary 17th 2023
Long-term safety data from the phase 3 ARAMIS rollover trial support the use of darolutamide in patients with nonmetastatic castration-resistant prostate cancer, according to an expert from the Carolina Urologic Research Center.
Abiraterone Combo Shows Sustained OS Benefit in Prostate Cancer SubtypeFebruary 17th 2023
In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.
Darolutamide/ADT Yields OS Benefit in mHSPC Across All Disease VolumesFebruary 17th 2023
Findings from the phase 3 ARASENS trial indicate that darolutamide plus androgen-deprivation therapy and docetaxel should be considered a new standard of care for metastatic hormone-sensitive prostate cancer.
Frontline Talazoparib/Enzalutamide Garners rPFS Benefit vs Placebo in mCRPCFebruary 17th 2023
Treatment with talazoparib and enzalutamide appears to yield a statistically significant and clinically meaningful radiographic progression-free survival benefit compared with placebo/enzalutamide in frontline metastatic castration-resistant prostate cancer regardless of homologous recombination repair status.
Sequencing Radioligands Appears to be Safe, Viable Strategy for mCRPCFebruary 16th 2023
Treatment with 177Lu-PSMA-617 results in similar survival benefit regardless of when it was administered after radium-223 in patients with metastatic castration-resistant prostate cancer, according to an expert from University Hospital of Münster in Germany.
Ponatinib Combo Demonstrates Superiority Vs Imatinib in Ph+ Leukemia SubtypeFebruary 16th 2023
An expert from the University of Texas MD Anderson Cancer Center says that ponatinib plus reduced-intensity chemotherapy may be a new standard of care for frontline Philadelphia chromosome–positive acute lymphoblastic leukemia.
NAPOLI-3 Study Answers ‘Important Question’ in Metastatic Pancreatic CancerFebruary 15th 2023
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
FDA Grants Priority Review to Avasopasem for Treatment-Related Oral MucositisFebruary 15th 2023
Data from the phase 3 ROMAN trial and the phase 2b GT-201 trial support the new drug application for avasopasem in radiotherapy-induced severe oral mucositis for those with head and neck cancer.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAsFebruary 14th 2023
A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
Momelotinib May Set New Standard in Myelofibrosis, Expert SaysFebruary 14th 2023
“Transfusion independence is the key to my excitement [with] momelotinib as a drug. I will likely use it in most patients in the second-line setting,” says an expert from the University of Texas MD Anderson Cancer Center.
Trilaciclib Reduces Neutropenia but Fails to Improve ORR in Metastatic CRCFebruary 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.